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ABSTRACT
A nucleic acid-based multiplexed assay was developed that combines detection of foot-and-
mouth disease virus (FMDV) with rule-out assays for two other foreign animal diseases and four 
domestic animal diseases that cause vesicular or ulcerative lesions indistinguishable from FMDV
infection in cattle, sheep and swine.  The FMDV “look-alike” diagnostic assay panel contains 
five PCR and twelve reverse transcriptase PCR (RT-PCR) signatures for a total of seventeen 
simultaneous PCR amplifications for seven diseases plus incorporating four internal assay 
controls. It was developed and optimized to amplify both DNA and RNA viruses simultaneously 
in a single tube and employs Luminex™ liquid array technology. Assay development including 
selection of appropriate controls, a comparison of signature performance in single and multiplex 
testing against target nucleic acids, as well of limits of detection for each of the individual 
signatures is presented. While this assay is a prototype and by no means a comprehensive test 
for FMDV “look-alike” viruses, an assay of this type is envisioned to have benefit to a laboratory 
network in routine surveillance and possibly for post-outbreak proof of freedom from foot-and-
mouth disease. 
Key Words:  Multiplex RT-PCR FMDV Rule-out
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1. INTRODUCTION:
Foot-and-mouth disease (FMD) is a highly contagious viral disease affecting domestic and 
wild ruminants and swine, and is characterized by vesicles on the tongue, gums, nose and feet.  
FMD has not been seen in the United States since 1929 but the disease is endemic in many parts 
of the Middle East, Africa, Asia and South America.  Periodically there are outbreaks in 
countries previously free of the disease, as demonstrated by the outbreak of FMD in the UK in 
2001 (Haydon et al. 2004).  That outbreak required the destruction of millions of animals, and
the disposal of their remains (Scudmore et al. 2002, Rweyemamu and Astudillo 2002). Travel
and trade restrictions had an estimated economic impact of more than $12 billion on travel, 
tourism, and many agriculturally-related industries (Thompson et al. 2002).
Diagnosis of FMD is confounded by other vesicular diseases that induce clinical signs in 
animals that are similar to those produced by FMDV. Testing for FMD and “look-alike”
diseases with conventional real-time RT-PCR requires performing multiple individual disease-
specific assays.  Combining individual assays for FMDV and “look-alike” diseases into a single 
diagnostic assay capable of differentiating FMDV from “look-alikes” could provide a very rapid, 
cost-effective means of viral identification.  Additionally, such an assay, if used for routine 
testing of diagnostic samples would significantly expand the number of tests performed on each 
sample, without significantly increasing the costs of the overall tests, or the time to results.  This 
type of testing enables routine surveillance for foreign animal diseases that might otherwise go 
undetected, and affords early detection, maximizing the amount of time available to the United 
States Department of Agriculture/Animal and Plant Health Inspection Service [USDA/APHIS] to 
respond to a foreign animal disease outbreak.  
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A multiplexed reverse transcriptase polymerase chain reaction (RT-PCR) liquid array 
assay was developed for the simultaneous detection and differentiation of FMD virus from six 
other viruses that cause vesicular diseases.  The liquid array technology employed for this assay
is described in the methods section.  Selection of viruses for inclusion in the panel was 
conducted in collaboration with the Department of Homeland Security (DHS) and the 
USDA/APHIS and based on end-user requirements.  The virus panel combines liquid array-
based testing for the detection of Foot and mouth disease virus (FMDV) [Family: Picornaviridae
Genus: Aphthovirus Species: Foot-and-mouth disease virus] two additional foreign animal 
diseases including Swine vesicular disease virus (SVDV) [Family: Picornaviridae, Genus:
Enterovirus, Species: Porcine enterovirus B, Serotype: Swine vesicular disease virus] and 
Vesicular exanthema of swine virus (VESV) [Fmily: Caliciviridae, Genus: Vesivirus, Species: 
Vesicular exanthema of swine virus] and four domestic “look-alike” disease viruses, including 
Bovine herpes virus-1 (BHV-1 aka infectious bovine rhinotracheitus) [Family: Herpesviridae, 
Subfamily: Alphaherpesvirinae, Genus: Varicellovirus, Species: Bovine herpesvirus 1] parapox
viruses including Bovine papular stomatitis virus (BPSV), Pseudocowpox virus (PCPV) and 
Contagious ecthyma of sheep virus (Orf virus) [Family: Poxviridae, Subfamily:
Chordopoxvirinae, Genus: Parapoxvirus, Species: Bovine papular stomatitis virus, 
Pseudocowpox virus, and Orf virus], plus Bovine viral diarrhea virus (BVDV) [Family:
Flaviviridae, Genus: Pestivirus, Species: Bovine viral diarrhea virus 1], and domestic 
Bluetongue virus (BTV) [Family: Reoviridae, Genus: Orbivirus, Species: Bluetongue virus].
The multiplexed assay panel (Table 1) comprises seventeen virus detection signatures, 
each consisting of a forward primer, reverse primer and probe designed to target unique genomic 
sequences of specific viruses. The two signatures for detection of FMD used in this multiplex 
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assay were developed by others and have been previously used for FMD laboratory diagnosis.  
One signature (5´UTR Pirbright) targets the ribosomal entry site of the 5´untranslated region 
(Reid et. al 2002) while the other signature (3D Tetracore) targets the viral RNA polymerase 
gene (Callahan et. al. 2002) on the FMDV genome. All viruses in the panel, with the exception 
of BVDV, are represented by two or more signatures. Additional signatures for the detection of 
BVDV that can be incorporated into the multiplexed panel are under development. Employing 
multiple signatures for a pathogen within the same assay, where those signatures target different 
genomic regions of the pathogen, increases the specificity of an assay and reduces the risk of 
false positives.  Using multiple signatures is even more important in an assay designed to detect 
rapidly-mutating pathogens like FMD where gene targets may change between virus generations
allowing for the pathogen to escape detection.  Such a gene target deletion has recently been 
identified for the bacteria Chlamydia trachomatis in a 377bp site in a plasmid used for clinical 
diagnosis of this pathogen by PCR (Ripa and Peter 2007).  Our detection algorithms require that 
all signatures for a pathogen must be positive in order for the sample to be ruled positive.  The 
assay also includes four internal controls.  The controls provide significant levels of increased 
confidence in the multiplexed assay results, as they have been designed to monitor and report 
each step of the assay.  The development, optimization and evaluation of the assay is described, a 
comparison of assay performance in both the singleplex and multiplexed environments is 
presented, and the utility of the assays for the simultaneous detection of multiple viruses from a 
single sample is demonstrated.  
2. MATERIALS AND METHODS
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2.1Liquid Bead Based Multiplex Array  The multiplexed assay was developed using 
Luminex™ flow cytometry-based technology. The liquid arrays (Figure 1a) utilize surface-
functionalized polystyrene microbeads embedded with unique ratios of two fluorophores (red 
and infrared).  Each unique dye ratio results in a distinct emission profile, a unique “spectral 
address”.  Because the microbead classes can be distinguished, they can be combined so that up 
to 100 different analytes can be measured simultaneously within the same sample.  The 
versatility of the liquid arrays has been well-demonstrated for detection of antibodies, antigens,
and peptides (McBride et al. 2003, Dunbar et al. 2003, Kellar and Iannone 2002, Perkins et al. 
2006). For nucleic acid-based detection, oligonucleotide probes with sequences that are 
complimentary to target nucleic acid sequences are covalently coupled to individual bead sets 
(Figure 1b).  These individual bead sets are then formulated into a mixture in a 1:1 ratio of all 
bead types.  Nucleic acids from pathogens (targets) are amplified using standard PCR techniques 
(Figure 1c).  After target amplification, the amplicons, half of which contain the biotinylated 
forward (5’-3’) primer, are introduced to the bead mixture, and allowed to hybridize to their 
complimentary probes on the corresponding beads (Figure 1d).  A fluorescent reporter molecule, 
strepavidin-phycoerythrin (SA-PE), is added and binds the biotin functional groups within the 
forward primers (Figure 1e).  The completed assay product is comprised of a bead + probe + 
biotinylated and fluorescently tagged amplicon (Figure 1e).  Each optically encoded and 
fluorescently labeled microbead is then analyzed by the flow cytometer.  Each individual bead 
within the sample is rapidly analyzed:  the 635-nm laser excites the dyes inside the bead, and 
classifies each bead to its unique bead class, while a 532-nm laser quantifies the assay at the bead 
surface.  Assays can be conducted from sample prep to results in a 96-well format in about three 
hours.
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2.2Buffers and Reagents  Tris-NaCl (0.1 M Tris, 0.2 M NaCl, 0.05 % Triton X, pH = 8.0), 
MES (0.1M 2-{N-morpholino}ethanesulfonic acid, 0.02 % Tween-20, 0.1 % SDS (sodium 
dodecyl sulfate), pH = 4.5), TE (Tris-EDTA, 10 mM Tris-HCl, 1.0 mM EDTA, pH = 8.0) 
buffers were purchased as custom formulations from Teknova Inc. (Hollister, CA).  Streptavidin-
R-phycoerythrin (Caltag Laboratories/ Invitrogen, Carlsbad, CA) was prepared and stored as a 
100X concentration (300 µg/mL) in Tris-NaCl, and diluted to a working concentration of 3.0
µg/mL just prior to use. 
2.3 Viruses  The following titered stocks of virus were purchased from the National Veterinary 
Service Laboratory(NVSL) (Ames, Iowa): BHV type 1(Colorado vaccine strain) in embryonic 
bovine kidney (EBK) cells, BTV serotypes 2 and 13 (no strain given) in baby hamster kidney 
(BHK) cells; BVDV genotype 1 (Singer strain, cytopathic) in EBK cells, and BPSV (Texas 
A&M strain) in EBK cells. The following seed viruses were purchased from the NVSL, grown 
and titered in BHK cells at LLNL: BTV-10 (lot #001 ODV 0001 Dec. 5, 2000, no strain given); 
BTV-11 (lot #002 ODV 0101 Nov. 30, 2001, no strain given); BTV-17 (lot #004 ODV 0201 
Nov. 28, 2002, no strain given). The following viruses were also grown and titered at LLNL: 
BHV-1 (L.A. strain) and BHV-1 (Texas strain) in Madin-Darby bovine kidney (MDBK) cells; 
Ovine contagious ecthyma (orf) vaccine virus (commercial strain) in embryonic bovine lung 
(EBL) cells; and BVDV (Singer strain) in MDBK cells.
The following foreign animal disease viruses (see supplemental data for strains used) 
were grown at Plum Island Animal Disease Center (PIADC): Swine vesicular disease virus
(SVDV) in SK6 swine kidney cells, Vesicular exanthema of swine virus (VESV) in Vero cells, 
and Foot-and-mouth disease virus (FMDV) in BHK cells.  The viruses were inoculated into 
flasks of 80% confluent cells and incubated at 37°C in 5% CO2.  The BHK, EBK, Vero and SK6 
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cells were grown in Eagle’s minimal essential medium with Earle’s salts and nonessential amino 
acids. Maintenance media also contained 2-4% fetal bovine serum, 2mM L-glutamine, 1.0 mM 
sodium pyruvate and added antibiotics. When cytopathic effect (CPE) reached 75-100%, the 
flasks were frozen at -70°C. The contents were later thawed, clarified and the supernatant 
aliquotted and stored at -70°C.  TCID50 titrations were performed in quadruplicate in 96 well 
plates. TCID50 values were calculated by the Spearman-Karber method (Finny 1978) for those 
viruses grown at NVSL and Plum Island and by the method of Reed and Muench (Reed and 
Muench 1936) for those grown at LLNL.
2.4 Target Nucleic acids.  Ninety one target virus strains and 51 near-neighbor virus strains were 
provided by collaborating diagnostic and reference laboratories and used to develop, optimize, 
and characterize the assays.  Near-neighbor strains are defined as genetically closely-related 
viruses.. Target viruses used for testing and optimization purposes are listed in Table 2, with 
additional details provided in the supplemental material.  BVDV, (single-stranded positive sense)
and BTV (double-stranded) RNAs were extracted with twice the volume of Trizol (Invitrogen, 
Carlsbad, CA), mixed, and incubated 15 min at 25C.  One-fifth of the total volume of 
chloroform was added, mixed, incubated 15 min at 25C and centrifuged at 3000 x g 15 min at 
4C. To the aqueous layer was added one half volume of isopropyl alcohol. The sample was 
mixed, incubated 10 min at 25 C, and then centrifuged 10 min at 12,000 x g at 4C. The pellet
was washed with 70% ethanol, dried briefly at 55C, dissolved in RNAse-free water and stored 
at -80  C. A measure of extraction efficiency was made using quantitative rT-PCR. The 
amount of RNA recovered from the direct extraction of a known amount of purified tobacco 
mosaic virus (TMV) was compared to the amount of TMV RNA recovered by extraction of the 
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same amount of virus from a culture supernatant containing titered BVDV or BTV. By this 
method, the Trizol RNA recovery efficiency was determined to be 98%. 
BPSV, Pseudocowpox, orf and BHV-1 DNA was extracted using a modification of a 
standard phenol/chloroform/ isoamyl alcohol protocol.  Triton X-100 (Sigma, St Louis, MO) and 
EDTA (Sigma) were added to virus samples to a final concentration of 0.5% and 20 mM,
respectively.  The mixture was vortexed, incubated 5 min. at 25  C, and centrifuged at 1000 x g
for 10 minutes; 10% sodium dodecyl sulfate (SDS) solution (Sigma) and Proteinase K (Roche, 
Indianapolis, IN) were added to a final concentration of 1 % and 4U/ml, respectively.  The
sample was held one hour at 55C with vortexing every 10 minutes, and allowed to cool to room 
temperature with the addition of NaCl to a final concentration of 150 mM.  An equal volume of 
phenol/chloroform/isoamyl alcohol (Sigma) in a 25:24:1 ratio was added, and the solution mixed 
thoroughly.  After 5 minutes at 25C, the mixture was centrifuged at 3,000 x g for 10 minutes.  
The aqueous layer was aliquotted (500 µl per tube) into microfuge tubes. To each tube, 1 ml of 
100% ethanol was added.  The tubes were incubated one hour at -20C and then centrifuged at 
18,000 x g for 10 minutes at 4°C.  The pellets were washed first with ice-cold 100% ethanol, 
next with ice-cold 70% ethanol containing 150mM NaCl, air-dried briefly, dissolved in 10 mM 
Tris-1 mM EDTA (TE) buffer and stored at -20C less than one month.  DNA extraction 
efficiency was determined by adding 50 pg of pUC18 to 0.95 ml of each virus sample before 
extraction.  The extracted virus/pUC18 mixtures were serially diluted 1:10 and assayed by 
quantitative PCR (qPCR). The concentration at which fluorescence levels failed to cross 
threshold in a pUC18 qPCR assay was compared to a second set of qPCR reactions using known 
concentrations of pUC 18. The efficiency of extraction was determined to be 100%.
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At Plum Island SVDV, VESV, FMDV were extracted using an Ambion Mag Max -96 total 
RNA isolation kit (Catalog #AM 1830) as per manufacturer’s protocols.
2.5 Background Nucleic acids.  Panels of “background” nucleic acid extracts were also used to 
determine specificity of the assays.  These included total nucleic acid extracts from 50 soil 
samples taken from multiple urban, suburban, and rural sites within the United States and during 
multiple seasons, 54 total nucleic acid extracts from prokaryotes, and 13 total nucleic acid 
extracts from eukaryotes (see supplemental materials for complete list of prokaryote and 
eukaryote backgrounds used).
2.6 PCR Primers. Candidate signatures (primer-probe triplets designed to target specific regions 
of a genome) were identified and selected using “KPATH”, a whole-genome nucleic-acid 
signature design system (Slezak et al. 2003).  All available complete or partial genomes for the 
virus targets in the multiplexed panel were computationally examined to identify sequence 
regions that were conserved among all sequenced isolates for the pathogen of interest but also 
unique to the target pathogen when compared against all available genomic sequence data in the 
KPATH database.  The conserved/unique sequence information was used to develop candidate 
signatures that met TaqMan and multiplex assay chemistry requirements.
     Oligonucleotide primers at 90% or more purity as determined by HPLC, were purchased as 
lyophilized pellets from Integrated DNA Technologies (IDT DNA, Coralville, IA).  Purification
of each lot was assessed by mass spectrometry and capillary electrophoresis. A 100 µM solution 
of primers was prepared in 10 mM TE buffer. Forward primers were purchased with 5’ biotin 
modifications and up to two additional internal biotin moieties.  Since biotin molecules are larger 
than nucleotide bases, the biotin molecules were separated by five to ten bases and were not 
placed at nucleotides next to the 3’ terminus of the forward primer to avoid interference with 
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amplification.  Internal biotin placement in the forward primers depended on thymidine location 
and quantity since thymidine is the attachment site for internal biotins.   
2.7 Probe Coupling to Luminex microbeads. Oligonucleotide probes were assigned to different 
sets of carboxylated fluorescent microbeads (Luminex Corp., Austin, TX).  To enable optimum 
hybridization, each probe sequence represented the forward compliment to the target region of 
the reverse strand (3’-5’), and contained a C-18 spacer between the reactive groups on the beads 
and the 5’ end of the oligonucleotide.  Probes for each of the pathogen targets were coupled to 
the beads using the manufacturer’s recommended coupling protocol (Wilson et al. 2005).
2.8 Preparation of Bead Mixture.  Bead mixtures were formulated for a 100 reaction mix where 
the total volume of 1X bead mix needed is 2200ul.  Four microliters of each conjugated bead 
class were mixed together with a volume of Tris-NaCl buffer sufficient to make the final volume 
of 2200ul.  To ensure that each microbead class was present in the bead mixture in 
approximately equal amounts, a 22 l aliquot was pulled from the 1X mixture, mixed with 78ul 
of Tris-Nacl (see buffers and reagents section) and analyzed with a Bio-Plex (Bio-Rad
Laboratories, Hercules, CA) instrument.  This ratio of 22:78 bead mixture to Tris-Nacl was used 
as it is equivalent to the concentration of beads in the final solution counted by the instrument 
after PCR hybridization (sec 2.10 below). The instrument was adjusted to count all bead classes 
in the sample to 1000 beads per bead class..  If the bead count of a particular class was low, a 
compensatory amount of that bead coupled to probe was added to the bead mixture. This was to 
insure that a particular microbead type is not limiting during the optical analysis. The bead 
mixtures were stored at 4 ºC in the dark before use.
2.9 PCR reagents.  All reactions were performed in a total volume of 25 μl (20 μl master mix 
plus 5 μl sample) optimized for multiplexed rT-PCR. A volume of 20 μl rT-PCR master mix 
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(Superscript III One-Step rT-PCR System, Cat#12574-026 Invitrogen, Carlsbad, CA) contains: 
12.5 μl 2X buffer (0.4 mM dNTPs, 3.2 mM MgSO4, and stabilizers), 1 μl Platinum Taq DNA 
polymerase and reverse transcriptase, 0.95 μl 50 mM MgSO4 (3.5 mM MgSO4 final 
concentration), 3.6 μl primer mix (0.4 M each forward and reverse primer final concentration) 
1.0 μl Alien- armoredRNA @ 100copies/l (used as internal control) and 0.95 μl water 
(Teknova). The armored RNA (XenoRNA-01, Ambion, Austin, TX) is a proprietary 1070 
nucleotide RNA transcript consisting of unique nucleotide sequences that possess no significant 
homology to the current annotated sequences in commonly used sequence databases.
2.10 Thermal cycling conditions:  Reverse transcription for cDNA synthesis was carried out at 
55º C for 30 minutes, followed by inactivation of the reverse transcriptase,  activation of 
Platinum Taq DNA polymerase, and denaturation of the RNA/cDNA hybrid at 95C for 2
minutes. Amplification was performed in a 96-well MJ Tetrad thermocycler (Bio-Rad) for 35 
cycles at 95ºC for 15 s, 60ºC for 30 s, 72ºC for 15 s, followed by a final extension of 72C for 2 
minutes and a 4C hold.  
2.11 Hybridization reaction:   Following rT-PCR amplification, 5 µl of PCR product was added 
to 22 µl of microbead mixture. The amplified product was denatured at 95°C for 2 minutes, and
hybridized at 55C for 5 minutes, and a 4C hold. Following hybridization 100 l of Tris-NaCl
buffer was added to the beads and this mixture was transferred to a pre-wetted 96-well filter 
bottom plate, 1.2 µm pore size (Millipore Corp., Billerica, MA), and washed 3x with 100 µl Tris-
NaCl to remove nonhybridized nucleic acids. The PCR products bound to the beads were labeled 
by adding 60 l SA-PE (streptaviden R-phycoerythrin conjugate 3 ng/l) and were incubated in 
the dark for 5 minutes. Beads were washed once with Tris-NaCl, re-suspended in 100 l Tris-
NaCl and analyzed in a Bio-Plex. 
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2.12 Titrations to Determine Limits of Detection: Serial dilutions of titered nucleic acids (as 
described above) spanning eight logs of concentrations were prepared and tested to assess the 
sensitivity and specificity of multiplexed assays.
3. RESULTS AND DISCUSSION 
3.1 Assay Development, Optimization, and Characterization. Primers from the KPATH design 
process (see methods 2.6) were tested against an extensive “background” panel of nucleic acids
derived from potentially-cross-reacting, interfering, or confounding sources to ensure that the 
primers detected the strain diversity of each pathogen but did not react with other nucleic acids
that could be present in a sample.  Primer pairs that successfully passed this wet-chemistry 
screening criteria were advanced to assay development, where extraction, PCR thermocycling 
and reaction procedure were optimized for consistent performance. One by one, each primer pair 
was evaluated against the full compliment of probes.  This approach allowed for the 
simultaneous assessment of individual assay sensitivity as well as specificity (as determined by 
the lack of reactivity of target nucleic acids with probes).  Suitable primer-pairs were then 
systematically incorporated into the multiplexed panel.  Using the complete panel of multiplexed 
signatures (Table 1), the screening was repeated with the backgrounds panel.  The performance 
of each signature was characterized in both simplex (a single primer-probe pair assay) and 
multiplexed (more than one primer-probe pair in an assay) formats.
The data presented in Table 2 summarizes the results of each step of initial assay 
development, and underscores the stringency of this process.  For example, KPATH identified 
177 potential candidate signatures for BHV-1. Each signature passed tests for uniqueness and 
conservation, and was predicted to detect target sequences, but not closely related sequences, in a 
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simulated multiplexed assay.  Of the 177 in silico candidate signatures, seventy-six were 
eliminated in the initial wet chemistry screening. Of the 101 remaining signatures, 97 were 
eliminated because they either did not detect all the target strains tested or they incorrectly cross-
reacted with near-neighbor strains (those viruses that are closely related at the genetic level and 
therefore have the greatest likelihood of cross-reaction). Only four signatures were suitable for 
inclusion in a multiplexed panel.  In further testing, only two of the four signatures performed 
well in the multiplexed environment.  These two signatures were tested in a multiplexed format
against thirteen different target strains to establish sensitivity, and twenty near-neighbors to 
determine specificity. Multiplex testing with targets involved titrations over eight logs of target 
dilution while single plex tests involved testing at one concentration of target to determine that a 
signature was reactive against a range of target strains. Thus as shown in Table 2 fewer target 
strains were screened in multiplex than in single plex but the same signature was used in both 
tests.
3.2 Internal Controls, Data Analysis and Interpretation.  When the flow cytometer completes a 
measurement, two important data parameters are displayed for each bead class used in the assay:  
the median fluorescent intensity (MFI) and the total number of beads counted.  Because the 
assays are conducted using a multi-step protocol and were designed for use in a large number of 
laboratories by many experimental scientists, a unique set of four rationally designed controls 
was developed (Table 1) and built into every sample to monitor and report on certain key steps 
of the assay.  A bead-conjugated Maritima (MT-7) oligonucleotide serves as the negative control 
(NC).  MT-7 is a conserved DNA sequence from a deep sea thermal vent microbe that does not 
match any published genomes of terrestrial organisms.  It serves as a measure of nonspecific 
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binding in the multiplexed assay.  In the absence of nonspecific binding, the MFI values for the 
NC MT-7 bead should remain consistently low.  A biotinylated MT-7 (b-MT7) oligonucleotide 
sequence, conjugated to a different bead, serves as the fluorescence control (FC).  The biotin 
moiety has a high affinity for avidin in the streptavidin phycoerythrin conjugate and confirms 
that the fluorescent labeling step of the assay was performed correctly.  MFI values of the b-MT7 
bead should be consistently high and constant from assay to assay.  Instrument control (IC) is 
accomplished with a bead conjugated to a Cy3-labeled MT-7 (MT7/Cy3).  Both Cy3 and SA-PE
have similar fluorescent excitation and emission wavelengths.  MFI values for the MT7/Cy3 
beads confirm that the flow cytometer reporter optics are functioning correctly.  Large 
fluctuations in the MFI values for MT7/Cy3 from sample to sample may indicate failure of the 
reporter laser.  Alien armored RNA, a synthetic RNA sequence approximately 1,000 nucleotides 
in length, packaged in an MS2 phage capsid, serves as an internal control for nucleic acid 
purification, rT-PCR amplification, microbead array hybridization and detection (Hietala and 
Crossley 2006).  These controls convey important diagnostic information regarding assay 
integrity; including reagent addition, quality and concentration; assay operator performance; and 
instrument stability.  These controls do not compromise or limit assay capabilities in any way.  
The raw data outputs from the flow cytometer typically require substantial analysis and 
interpretation, as compared to data outputs from conventional real-time PCR assays.  To simplify 
this process and ensure uniform interpretation of sample results between laboratories, detection 
algorithms to guide interpretation were developed.  Threshold MFI values for each signature 
were established that enable results to be classified as either positive (analyte present) or 
negative (analyte absent).  Threshold determination for these assays and the mathematical 
principles that underlie our algorithm development will be described in detail in a manuscript in 
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preparation. A positive / negative designation was made for each unknown sample by 
comparing each individual signature's MFI value with a threshold.  Threshold values for each 
signature were calculated based on the distribution of MFI responses to a large number (> 1000) 
of known negative clinical samples obtained from thirteen state veterinary diagnostic labs from 
throughout the United States.  A threshold value for each individual signature was chosen such 
that the MFI values generated by each signature in response to the set of negative samples would 
exceed threshold at a rate of 0.005 (or 1 per 500 samples). To run the algorithm, MFI values for 
the four internal controls were checked first.  If the MFI value for any control was out of range, 
assay results were deemed invalid.  However, if the MFI for the Alien armored RNA control and 
one or more MFI values for the seventeen agents exceeded threshold, that sample were then 
deemed valid and included in further analysis. Agent MFI spikes above certain concentrations 
have been observed by our laboratory to cause a decrease in the MFI of the Alien armored RNA, 
probably due to competition in the PCR reaction. If the MFI of Alien armored RNA dropped 
below threshold on a sample considered negative for all signatures, the sample was repeated. 
This control reduces the probability of false negatives.  If the MFI values for all four controls fall 
within range, the bead counts are checked.  Minimum bead counts of 40 beads per bead class 
must be attained for the result to be considered valid.  If a viral signature sample did not reach 
the 40 bead minimum, the assay result was deemed invalid for that viral sample.  If the bead 
counts for any of the viral signatures exceeded the minimum, they were considered valid. 
In addition to multiple internal controls, multiple signatures for a single virus enhances
confidence in the assay result.  A single signature, designed to target a specific genomic region 
may not detect certain strains that do not have that exact sequence in their genomes.   The use of 
multiple signatures, where each signature targets different genomic regions of the same pathogen 
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increases the probability of detection and increases the number of strains or serotypes that the 
assay can detect.  Our detection algorithms are designed to minimize the probability of false 
positives.  For example, three signatures specific for a given virus are required to exceed their 
individual threshold values before a sample can be ruled positive.  Each signature in the 
multiplexed assay has been selected such that it has a probability of false positive rate of 0.002.  
Thus, the likelihood of a false positive becomes 0.0023 (approximately1 false positive per 100
million samples).  Depending on signature design, the relative responses to different signatures 
may convey additional information about strain types or serotypes.  
3.3 Comparison of Assay Performance in Singleplex versus Multiplexed formats.  Figure 2 
shows representative titration curves comparing the performance of individual signatures for the 
detection of three viruses (BHV-1, parapox, and BTV) in both simplex (closed circles) and 
multiplexed (open circles) formats.  Dose-response curves were generated using nucleic acids 
extracted from the viral stock solutions described previously, diluted over eight log units (X-
axis) and plotted against the log of the median fluorescent intensity (MFI) as reported by the 
flow cytometer software (Y-axis).  Each data point of each curve represents the average of three 
replicate samples.  Background fluorescence measured using PCR reagents with no nucleic acid 
target is given by the first data point in each curve.  
Like the examples shown in Figure 2, all seventeen individual virus detection signatures in 
the multiplexed assay produced a reproducible response above background over 3-4 logs of 
concentration.  The limit of detection (LOD) was defined as the target nucleic acid concentration 
at which the MFI value is 2.5 times the standard deviation of the background.  For the signature 
comparison shown in Figure 2, no differences between the limit of detection obtained in simplex 
and multiplexed formats were observed.   
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Limits of detection for every signature within the multiplexed assay panel are summarized in 
Table 3.  Limits of detection were generally lower for RNA viruses than for DNA viruses in the 
multiplexed format. This may have been due to the fact that the total number of RNA viruses 
was much higher than the number of RNA virions. Evidence indicates large differences in the 
ratio of viral particles to plaque-forming units [PFU] or infectious units for different RNA 
viruses.  Different strains of poliovirus which, like FMDV, is a member of the Picornaviridae
family, have been shown to have particle-to-PFU ratios ranging from 30 to 1,000 whereas strains 
of Semliki Forest virus, a member of the Alphaviridae, has a particle-to-PFU ratios of 1-2 (Flint 
et. al., 2004).  Thus, the large variations in sensitivity differences may be due to variations in the 
number of infectious virions present.  Alternatively, the one-step RT-PCR kit used in the 
comparison may not be optimal for the amplification of double-stranded DNA.  Even the least 
sensitive assay, however, could detect 500 infectious units while the most sensitive could detect 
three logs less than one infectious unit.  
The background fluorescence for each signature-bearing bead class (Table 3) was slightly 
different due to the inherent differences of the dye ratios in the beads in addition to the non-
specific interaction of their probe moiety. In general, the baseline MFI values were between 5-
20 in the simplex format (data not shown), and 5-65 in the multiplexed format.  Background 
fluorescence values tended to be higher in the multiplexed format, most likely due to the more 
complex chemical environment produced by the large number of primers and/or due to an 
increase in nonspecific binding.  
3.4 Simultaneous Detection of Nucleic Acids using the Multiplexed Assay Panel
To determine if the multiplexed RT-PCR assay could simultaneously detect multiple nucleic 
acids from different viruses in a single tube, samples containing both RNA and DNA from 
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domestic look-alike viruses were tested. Identical concentrations of BHV-1, BPSV, BVDV, and 
BTV, were combined to produce a master stock. The results are shown in the three-dimensional 
plot (Figure 3). The plot displays the results of eight individual assays, where each sample 
represents a serial dilution spanning 7 logs (Z-axis) of the master stock.  Assay results included 
all of the 17 signatures and the four controls (X-axis): the controls have been omitted for clarity
but were within expected limits (data not shown). MFI values are plotted on the Y-axis. The 
MFI values for each of the corresponding signatures increased with increasing concentration of 
mixed target nucleic acid, even in the presence of high concentrations of multiple targets. The 
nine signatures corresponding to the non-target viruses did not react even at the highest 
concentrations of amplified nucleic acids.  These results demonstrate the high detection
specificity of each component of the multiplexed assay panel.  Moreover, despite the complex 
chemistry of the multiplexed assay, the simultaneous detection and differentiation of four 
different RNA and DNA viruses occurred with no increase in limit of detection (loss of 
sensitivity) for any signature with any target.  Non-target foreign animal disease virus assays 
(FMDV, SVD, VESV) do not exhibit any elevated signal in complex viral sample matrices, 
illustrating the sensitivity and specificity of the multiplex assays,
The ability of the multiplex assay to detect multiple strains of targets was tested by using 1
ng of total RNA extract from virus culture supernatants showing cytopathic effect [CPE].  Thirty 
one FMDV isolates were tested in this way, and both FMDV signatures were found to be 
reactive to 29 of the 31 strains.  Only the Tetracore signature showed a positive signal for two of 
four SAT2 isolates tested.  Similarly, all four VESV signatures were positive for two of  eight
VESV isolates tested, with the remainder demonstrating different combinations of signatures 
showing positive signal on different isolates (see supplementary material).  The signature 
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targeting the putative VPg gene (VESV-4) was most robust and was able to detect all eight
isolates.  This result is most likely a result of the conservation of this gene.  The most robust 
individual SVD signature, showing a positive signal for all 27 isolates, was the SVD-1 signature 
targeting the viral capsid gene, while the least robust signature, SVD-3 targeting the viral 
replicase was positive for only 6 of 27 isolates tested.  This result was unexpected as 
conservation of the replicase gene would be expected over and above that of the viral coat 
protein however other factors such as amplicon length and probe hybridization can affect the 
ability of a signature to detect a target virus genome. SVD-2 was positive for 25 of 27 isolates 
tested. For all isolates of BVDV, BTV, parapox, and BHV-1 target tested, all signatures targeting 
those agents were positive with no cross-reactivity seen.
Finally, as indicated in Table 2 and supplementary data, this multiplex assay does not show 
cross-reactivity with any of a large number of near-neighbor viruses tested.  None of the 17 
target signatures showed any cross-reactivity when tested against 1ng of total RNA extract from 
viral culture supernatants showing CPE collected from eight porcine enterovirus strains, six
bovine enterovirus strains or human enterovirus coxsackie B5.  Only the BVD-1a signature 
showed elevated MFI signals when the multiplex assay was tested against four epizootic 
hemorrhagic disease virus strains, a genetic near-neighbor to BTV.  Further investigation 
revealed that the tissue cultures used to propagate these BTV near-neighbor viruses was 
contaminated with BVDV-positive fetal bovine serum.  The elevated MFI signals for the BVD-
1a were encountered with four equine herpesvirus and one feline herpesvirus isolates (all near-
neighbors of BHV-1).  Of all near-neighbor viruses tested, only the VESV-4 signature, the one 
demonstrated to be able to detect all VESV isolates, cross-reacted with the San Miguel sealion 
virus Type 2 [SMSV-2].  This result would be expected due to the close genetic relationship 
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between VESV/SMSV which shows these viruses belong to a single genotype distinct from other 
caliciviruses (Reid et. al. 2006).
In summary, the assay demonstrates robust detection of all targets tested with at least one 
signature showing positive signal for some, while multiple signatures showed positive signal on 
the vast majority of targets tested with no cross-reactivity observed.  Additionally, no near-
neighbor viruses showed any cross-reactivity with any of our signatures.
4. Conclusions
A first generation, rapid, highly multiplexed nucleic acid assay for the detection of 
FMDV and its differentiation from other viruses that cause symptoms indistinguishable from 
those of FMDV has been developed.  Using seventeen virus detection signatures, the assay 
sensitivity in singleplex and multiplexed assay formats for several signatures has been shown to 
be comparable. A much more extensive evaluation of the overall assay sensitivity and 
specificity is underway in addition to test utilizing actual clinical samples.  To demonstrate the 
robustness of the assays, an inter-laboratory comparison has been conducted at thirteen National 
Animal Health Laboratory Network (NAHLN) labs throughout the United States and at Plum 
Island Animal Disease Center (PIADC; results will be reported elsewhere).
The multiplexed liquid array-based assay described can be used for the simultaneous 
detection and differentiation of multiple DNA and RNA viruses in a single sample with the 
ultimate benefit of savings in both time and money, compared to traditional single tests for
infectious agents. In the event of a disease outbreak, this assay approach can also be adapted to 
high throughput processing using robotic sample handling, sample barcoding and new data 
reporting software. This capability was demonstrated at the University of California, Davis in 
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May, and at Colorado State University in July of 2006. (results will be reported elsewhere). The 
assay described is a prototype and is by no means a comprehensive test for FMD “look-alike” 
viruses of cattle, pigs and sheep. Refinements to the prototype assay are currently underway, 
which include the development of two species-specific panels for cattle and pigs that provide 
more comprehensive FMDV “look-alike” virus coverage. These second-generation multiplexed 
assays will be more comprehensive, with a species-specific emphasis, and when fully-validated, 
could enhance preparedness and response capabilities of both state and federal veterinary 
diagnostics laboratories by enabling them to pair surveillance for FMDV with differential testing 
for the “look-alike” disease viruses. 
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Figure 1. A) 100-plex liquid array generated by varying the ratios of red and infrared dyes embedded in 
polystyrene latex microbeads.  Each optically encoded bead has a unique spectral address.  B) Capture beads with 
covalently-coupled oligonucleotide probes complimentary to target nucleic acid. C) Individual primer pairs
(biotinylated forward and standard reverse) that bracket the target genomic sequence are included in a PCR master 
mix of buffers, Taq polymerase, dNTPs, etc.  After amplification by PCR, the amplicons are mixed with beads 
where target amplicons containing the forward biotinylated primers hybridize to the complimentary probe on the 
appropriate beads. D)  A fluorescent reporter molecule (streptavidin-phycoerythrin) then binds biotin functional 
groups.  E)  The completed assay comprises a bead + probe + biotinylated (and fluorescently tagged) amplicon.  The 
sample is then analyzed using the flow cytometer.  
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Figure 2.  Titration curves  Singleplex/Multiplex
 BHV-1 signature 3, BPSV signature 1, BTV signature 2
Figure 2. Log of the MFI vs virus RNA concentration in infectious units for a simplex (open circles) or 
multiplex (solid circles) assay. In each of the three plots, a signature is titrated against eight logs of diluted 
RNA or DNA from known amounts (TCID50) of the target virus is shown. Left plot response of bluetongue 
virus signature 2 titrated against RNA extracted from BTV serotype 13. Center plot is the bovine papular 
stomatitis (BPSV) signature 1 titrated against DNA extracted from BPSV Texas A&M strain. The right plot 
is the response of bovine herpes virus (BHV-1) signature 3 titrated against DNA extracted from BHV-1 
Colorado vaccine strain. 
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Figure 3. A specific and robust response of the multiplex assay to a mixture two different RNA 
and two DNA nucleic acids from four target viruses (BTV, BPSV, BHV and BVD).  MFI of each 
assay is plotted on the z axis, viral concentration (shown as serial dilutions) along the y axis, and 
each individual signature is shown along the x axis. At the nucleic acid concentration of 1.3E -04 
all the signatures show background MFI values. As the concentration of viral nucleic acid 
increases for the target viruses the MFI values for those assays are seen to tirate. The other 
channels for non target viruses remain unreactive even in the presence of this complex viral 
nucleic acid mixture.
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Table 1.  Summary of Components of Multiplexed Panel 
Signature Forward Primer (5' -3') Reverse Primer (5' -3') Probe (5' -3') Ampliconlength Gene Target
Bovine Herpes 
Virus sig 1
GTGCCAGCCGCGTAAAAG GACGACTCCGGGCTCTTTT TCCTGGTTCCAGAGCGCTAACATGGAG 140bp Glycoprotein C (UL43)
Bovine Herpes 
Virus sig 3
TGAGGCCTATGTATGGGCAGTT GCGCGCCAAACATAAGTAAA AAATAACACGGTGTGCACTTAAATAAGATTCGCG 114bp Glycoprotein B (UL27)
Bovine Papular 
Stomatitis Virus 1
GCAGATGCGCTCCTGGTT GCACCTCTGCTGCTGCAA CCGACTCCGACGTGGAGAACGTG 178bp DNA Packaging Protein/ATPase
Bovine Papular 
Stomatitis Virus 2
GATGGCCGTGCAGCTCTT CGTACAAGATCACGGCCAACT TGTACGGGCTCATGGGCTTCCG 95bp DNA Polymerase
Bovine Papular 
Stomatitis Virus 4
GCAGCAGTGCACCACGTAGT CGCTGAACCCGTACATCCT GACTTCGAGGCGGACAACAAGCG 167bp Early Transcription Factor [VETFL]
Foot and Mouth 
Virus (Tetracore)
ACTGGGTTTTACAAACCTGTGA GCGAGTCCTGCCACGGA GTCCCACGGCGTGCAAAGGA 107bp 3D Polymerase
Foot and Mouth 
Virus (Pirbright)
CACYTYAAGRTGACAYTGRTACTG
GTAC
CAGATYCCRAGTGWCICITGTTA CCTCGGGGTACCTGAAGGGCATCC 97bp 5' UTR
Bovine Viral 
Diarrhea sig 1
GGTAGTCGTCAGTGGTTCGAC  CATGTGCCATGTACAGCAGAGAT  CCTCGTCCACGTGGCATCTCGAG 195 bp Mature Peptide N-Pro
Bluetongue
Virus sig 2
GCACCCTATATGTTTCCAGACCA CAGCTAACTCTTCAGCCACACG CTAACTCGTGGGCCAATCATCATCTTCTGT 271bp VP1 RNA polymerase
Bluetongue 
Virus sig 3
AGAATTCAGGATGGGCAGGA GCACAATTCCCATCCCCTTA CCATCACACCATTATACTGTACCCGCGTAGC 187bp NS2 RNA binding protein
Swine Vesicular 
Disease 1
CAGGATAATTTCTTCCAAGGGC ACGTGAACATTTCGAGCTTCC TGCATTGTGTCTGATGGTACAACTTGTGACG 349bp Viral Capsid Protein/VP1
Swine Vesicular 
Disease sig 2
GACTTGTTGTGGCTGGAGGA CAGCGCCATGGTGAGGTAG TGACCGTAATGAGGTCATCGTGATTTCTCAC 281bp Membrane Permeability Enhancement [Protein 2B]
Swine Vesicular 
Disease sig 3
GACAAAGTGGCCAAGGGAAA CACGTAAACCACACTGGGCT CTGGCGTCATAGCCTGAATAGTCAAACGCTA 248bp RNA Dependant RNA Polymerase [Protein3D]
VESV 1 GCCTTCTCCCTTCCCAAAA TGAAGGAATGGTTCCGTCAGT CATCATCGTTGATAACCTTAGATGTGCAATTTGG 153bp Putative N-terminal Leader Protein[2B Ortholog]
VESV 3 GGGAATGAGGTGTGCATCATT CACGTCTTGATGTTGGCTTGAC AAATTGGCATAATCAACCTTGTCAGATGAGTCG 199bp NTPase Protein [2C Ortholog]
VESV 4 GGTCGCTCTCACTGATGATGAGTA GGTGTTATCAGCACCCATTGC GCTCGGTGCCTGAGTTGGAGGAAG 124bp Putative VPg
VESV 5 ACCACCTCTGGAAACATCTATGG TTTGTGCACGTGTCACGAAT CGGGACGGGCATTTGTCACCA 200bp Putative Cysteine Protease
Maritima 7 (NC) N/A N/A CAAAGTGGGAGACGTCGTTG N/A Assay Negative control
Biotin-maritima 7 
(FC) N/A N/A CAAAGTGGGAGACGTCGTTG N/A Stepavidin Phycoerythrin control
Cy3-labeled 
Maritima 7 (IC) N/A N/A CAAAGTGGGAGACGTCGTTG N/A Instrument control
Alien-RNA PCR 
control Propriatary sequence Propriatary sequence Propriatary sequence N/A PCR and extraction control
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Table 2.  Summary of Assay Development, Optimization and Characterization
Target 
analyte
#of computer-
generated 
candidate 
signatures
# of 
signatures 
forwarded to 
Real-time 
PCR
# of 
signatures 
released to 
multiplex
# of 
signatures 
in final
panel
# target 
strains 
tested
singleplex
# target 
strains 
tested 
multiplex
# near-
neighbor 
strains 
tested
BPSV 8 7 4 3 4 2 9
Orf 8 7 4 3 3 1 9
BHV 177 101 4 2 10 13 20
BVD 1 1 1 1 1 2 0
FMDV 4 4 4 2 29 7 42
BTV 8 8 4 2 5 5 4
SVD 4 4 4 3 30 11 47
VESV 44 20 6 4 12 11 2
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Table 3.  Summary of Multiplexed Assay Performance Against Selected Strains
Signature Test Strain Multiplex LOD
[Infectious Units]
Background
MFI
Threshold 
MFI
Bovine Herpes Virus-1 #1 CO Vaccine 500 30 >49
Bovine Herpes Virus-1 #3 CO Vaccine 500 40 >43
Bovine Papular Stomatitis Virus #1 Texas A&M 500 30 >35
Bovine Papular Stomatitis Virus #2 Texas A&M 50 65 >400
Bovine Papular Stomatitis Virus #4 Texas A&M 500 35 >41
Foot and Mouth Disease Virus 
(Tetracore)
01 Korea 2.7X10-1 10 >42
Foot and Mouth Disease Virus 
(Pirbright)
01 Korea 2.7X102 10 >60
Bovine Viral Diarrhea #1 Singer 
Cytopathic
50 30 >40
Bluetongue Virus #2 NVSL serotype 
13
5 30 >55
Bluetongue Virus #3 NVSL serotype 
13
50 20 >31
Swine Vesicular Disease #1 ITL 1-66 20 8 >38
Swine Vesicular Disease #2 ITL 1-66 200 10 >28
Swine Vesicular Disease #3 ITL 1-66 20 16 >40
VESV #1 E54/A48 1.3 5 >24
VESV #2 A48 1.3X10-3 18 >39
VESV #4 E54/A48 1.3X10-2 17 >105
VESV #5 A48 1.3X10-3 20 >56
Notes: Data is reported in absolute units, assuming that 5 µl of sample is added to each reaction.  
Two methods were used for determination of infectious units: FMDV strains were titered in
plaque-forming units. All other viruses were quantitated in tissue culture infectious doses 50% 
endpoint (TCID50).  Infectious units refer to either TCID50 or PFU, and are not extrapolations 
from an equation.  
